d-Methadone for the treatment of psychiatric symptoms
The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.
1. A method of treating psychological and psychiatric symptoms comprising:
administering a composition to a subject suffering from one or more psychological symptoms chosen from depression, anxiety, fatigue, and mood instability including pseudo-bulbar affect, the composition including, as the sole active agent for treating said one or more psychological symptoms, an NMDA receptor antagonist selected from d-methadone, d-methadol, d-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, and pharmaceutically acceptable salts thereof;
wherein the NMDA receptor antagonist is isolated from its enantiomer or synthesized de novo; and
wherein the administering of the composition occurs under conditions effective for the NMDA receptor antagonist to bind to an NMDA receptor of the subject and thereby relieve the subject from said one or more psychological symptoms.
2. The method according to claim 1 , wherein the NMDA receptor antagonist is d-methadone.
3. The method according to claim 2 , wherein the NMDA receptor is capable of biological action, and wherein the administering is effective to block the biological action of the NMDA receptor.
4. The method according to claim 2 , wherein the subject has a central nervous system, and wherein the NMDA receptor is located in the central nervous system.
5. The method according to claim 4 , wherein the subject is a mammal.
6. The method according to claim 5 , wherein the mammal is a human.
7. The method according to claim 2 , wherein the d-methadone in the form of a pharmaceutically acceptable salt.
8. The method according to claim 2 , wherein the d-methadone is administered intravenously.
9. The method according to claim 2 , wherein the d-methadone is delivered at a total daily dosage of about 1 mg to about 5,000 mg.
10. A method of treating psychological and psychiatric symptoms comprising:
administering a composition to a subject suffering from one or more psychological symptoms chosen from depression, anxiety, fatigue, and mood instability including pseudo-bulbar affect, the composition including, as the sole active agent for treating said one or more psychological symptoms, an NE reuptake inhibitor selected from d-methadone, d-methadol, d-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, and pharmaceutically acceptable salts thereof;
wherein the NE reuptake inhibitor is isolated from its enantiomer or synthesized de novo; and
wherein the administering of the composition occurs under conditions effective for the NE reuptake inhibitor to bind to an NE receptor of the subject and thereby relieve the subject from said one or more psychological symptoms.
11. The method according to claim 10 , wherein the NE reuptake inhibitor is d-methadone.
12. The method according to claim 11 , wherein the NE receptor is capable of biological action, and wherein the administering is effective to inhibit NE reuptake at the NE receptor.
13. The method according to claim 11 , wherein the subject has a central nervous system, and wherein the NE receptor is located in the central nervous system.
14. The method according to claim 13 , wherein the subject is a mammal.
15. The method according to claim 14 , wherein the mammal is a human.
16. The method according to claim 11 , wherein the d-methadone in the form of a pharmaceutically acceptable salt.
17. The method according to claim 11 , wherein the d-methadone is administered intravenously.
18. The method according to claim 11 , wherein the d-methadone is delivered at a total daily dosage of about 1 mg to about 5,000 mg.